1 National Cancer Institute, Hematology and Bone Marrow Transplantation unit.
2 Nasser Institute Hospital for research and treatment, Hematology and Bone Marrow Transplantation unit.
3 Kasr Alainy, faculty of medicine, Cairo University, Hematology and Bone Marrow Transplantation unit.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
stem cell transplantation (HSCT) is now an established treatment
modality with definitive indications for many hematological disorders.
However, HSCT requires tremendous resources, and it is increasingly
challenging for transplantation experts to practice in the developing
world and to reach a compromise between requirements and available
resources. Based on 30 years of experience and 4256 transplants (60%
allogeneic and 40% autologous), this article focuses on the challenges
our HSCT program encountered since it started in 1989 and what
opportunities we see to solve them. Since 1997, HSCT procedures
increased dramatically with the opening of 15 HSCT units distributed
all over Egypt.
|Table 1. Patients underwent allogenic and autologous stem cell transplantation.|
Challenges facing hematopoietic stem cell transplantation in Egypt
|Table 2. Number of patients underwent Haploidentical HSCT in our center.|
|Figure 1. Overall survival of our 201 BTM cases after a median follow-up period of 12 years.|
|Figure 2. Overall survival of our 63 FA patients after six years of follow up.|
|Figure 3. The use of PTCY in prophylaxis of malignant and non-malignant disorders receiving HLA-matched transplants.|
|Figure 4. The use of PTCY in prophylaxis of 29 AML cases receiving HLA-matched transplants.|
Pneumocystis Jirovecii Pneumonia (PJP)